Federal contract award

36C25523N0373

OPT 3 - VISN 15 - BLOOD CULTURE SYSTEM, TO INCLUDE REAGENTS, VIRTUO EQUIPMENT , MYLA MIDDLEWARE, PHYSICAL SERVERS, AND SUPPORT DURING POP: 08/01/2023 - 07/31/2024

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Veterans Affairs
Office255-NETWORK CONTRACT OFFICE 15 (36C255)
NAICS325413 — In-Vitro Diagnostic Substance Manufacturing
PSC6550 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
Parent award / vehicle36C25520D0027
Set-asideNot reported
Pricing typeFIRM FIXED PRICE
Obligations$421.7K
Current contract value$421.7K
Potential contract value / ceiling$421.7K
Start dateAug 1, 2023
Current end dateJul 31, 2024
Potential end dateJul 31, 2025
Latest award activityApr 3, 2026
Source loadedSep 19, 2026

Funding and modification history

Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Apr 3, 2026P00009$-29.3KDE-OBLIGATE EXCESS FUNDS FOR PO 589C32254-TOPEKA AND 589C30242 KANSAS CITY. 03/26/26-DE-OBLIGATION EXCESS FUNDS FY23 -$29,330.40 STL.
Apr 10, 2025P00008$-2.6KDE-OBLIGATE EXCESS FUNDS FOR PO 589C32254-TOPEKA AND 589C30242 KANSAS CITY.
Feb 5, 2025P00005$-6.9KVISN 15 - BLOOD CULTURE SYSTEM DECREASE EXCESS FUNDS FOR CMOVAMC DECREASED BY $6,871.30 FROM $85,194.80 TO NOW READ $78,323.50
Jan 24, 2025P00007$6.5KVISN 15 - BLOOD CULTURE SYSTEM, INCREASE FUNDING TO PAY FINAL INVOICE
Dec 12, 2024P00006$1.5KVISN 15 - BLOOD CULTURE SYSTEM, INCREASE FUNDS FOR POPLAR BLUFF
Nov 21, 2024P00004$-1.6KVISN 15 - BLOOD CULTURE SYSTEM, DECREASE EXCESS FUNDS FOR POPLAR BLUFF
Nov 13, 2024P00003$-320VISN 15 - BLOOD CULTURE SYSTEM, DECREASE EXCESS FUNDS FOR MARION

Research next steps

  1. Verify whether remaining options may extend performance beyond the current end date.
  2. Confirm the ordering vehicle and your eligibility or a qualified teaming route.
  3. Review the award scope and buyer evidence before making a bid/no-bid decision.